We are
a group of innovative Biotech companies continuously growing and rapidly evolving through the constant establishment of Strategic Alliances in a wide range of Biotechnological areas.
Pipeline is comprised of innovative drug candidates in the fields of Hemostasis and Thrombosis. Some of these compounds, as our recently Orphan Drug Designated
TT-103MH topical antihemorrhagic recombinant protein, are available for licensing out.
We also have new anticoagulants, antifibrinolytics, antiplatelet agents, and are working on innovative gene therapies for the treatment of coagulation disorders.
Contact
www.
Thrombotargets.com
General:
info@thrombotargets.com
